M
any nonbiologic disease-modifying antirheumatic drugs (DMARDs) are available for treating active rheumatoid arthritis (RA). Methotrexate, alone or in combination, is most commonly used. However, methotrexate alone is not always appropriate because of inadequate efficacy (1) , and approximately 10% to 30% of patients with RA discontinue it because of toxicity (2) . Therefore, it is important to investigate whether treatments with novel mechanisms of action are safe and effective when dosed in combination with various nonbiologic DMARDs commonly used for the treatment of RA.
Tofacitinib (CP-690,550) is a novel, oral, Janus kinase (JAK) inhibitor for the treatment of RA. Tofacitinib inhibits JAK1, JAK2, and JAK3 and, to a lesser extent, tyrosine kinase 2 (3, 4) . Intracellular pathways for transducing receptor signals that include these kinases are critical to immune cell activation, proinflammatory cytokine production, and cytokine signaling (5) that are thought to mediate RA pathophysiology.
In earlier dose-ranging, randomized, controlled trials, tofacitinib as monotherapy and in combination with background methotrexate was efficacious with a well-defined safety profile in patients with active RA. Safety risks associated with tofacitinib included infection, lipid elevations, anemia, neutropenia, aminotransaminase elevations, and increases in serum creatinine (6, 7) . Large-scale trials were subsequently designed to investigate tofacitinib, 5 mg and 10 mg twice daily, as monotherapy and in combination with methotrexate and various other nonbiologic DMARDs.
We report a large-scale clinical trial of tofacitinib in combination with several nonbiologic DMARDs in patients with active RA and an inadequate response to at least 1 nonbiologic or biologic DMARD.
METHODS

Design Overview
We conducted a randomized, 1-year, double-blind, placebo-controlled, clinical trial conducted at 114 centers in 19 countries from 18 May 2009 (first patient, first visit) to 17 January 2011 (last patient, last visit). The trial involved 2 groups receiving 1 of 2 doses of tofacitinib and 2 groups receiving placebo. Patients randomly assigned to placebo advanced to tofacitinib treatment at month 6 or, if they did not respond at an earlier assessment, at month 3. The study was conducted in compliance with the Declaration of Helsinki and all International Conference on Harmonisation Good Clinical Practice guidelines. The study (Pfizer protocol A3921046) was registered with ClinicalTrials.gov (NCT00856544) and approved by the institutional review boards or independent ethics committees for each study center. All patients provided written informed consent.
Setting and Participants
Enrolled patients were aged 18 years or older with an RA diagnosis consistent with the 1987 American College of Rheumatology (ACR) revised criteria (8) . Key inclusion criteria included active RA defined by 4 or more tender or painful joints, 4 or more swollen joints (68-or 66-joint count), and an erythrocyte sedimentation rate (ESR; Westergren method) of 28 mm/h or greater or a C-reactive protein level greater than 66.7 nmol/L. Patients were required to have an inadequate response to treatment with 1 or more stably dosed nonbiologic or biologic DMARDs before baseline and to continue treatment with 1 or more background nonbiologic DMARDs at stable doses throughout the study. Patients receiving background methotrexate (Յ25 mg/wk) required at least 4 months of therapy with stable dosing 6 weeks before receiving the study drug. All disallowed DMARDs (defined as biologic DMARDs, potent immunosuppressives [such as cyclosporine and azathioprine], and any DMARD that would be contraindicated according to the local prescribing information) had to be discontinued. Background, low-dose, oral corticosteroid therapy with stable dosing (prednisone, Յ10 mg daily, or equivalent) was permitted.
Key exclusion criteria at screening were previous treatment with lymphocyte-depleting therapies within 1 year of randomization or alkylating agents at any time; hemoglobin level less than 90 g/L, hematocrit less than 30%, leukocyte count less than 3.0 ϫ 10 9 cells/L, neutrophil count less than 1.2 ϫ 10 9 cells/L, or platelet count less than 100 ϫ 10 9 cells/L; estimated glomerular filtration rate of 40 mL/min per 1.73 m 2 or less (Cockcroft-Gault equation); aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than 1.5 times the upper limit of normal; history of another autoimmune rheumatic disease other than the Sjögren syndrome; history of cancer (except treated nonmelanoma skin cancer and cervical carcinoma in situ); infection that required hospitalization or parenteral antimicrobial therapy within 6 months of randomization, infection requiring antimicrobial therapy within 2 weeks of randomization, recurrent or disseminated herpes zoster infection, or infection with hepatitis B or C virus or HIV; and evidence of Mycobacterium tuberculosis infection.
Randomization and Interventions
Patients were randomly assigned 4:4:1:1 at baseline to 1 of 4 twice-daily treatment sequences: 5 mg of tofacitinib, 10 mg of tofacitinib, placebo advanced to 5 mg of tofacitinib, and placebo advanced to 10 mg of tofacitinib. At month 3, placebo recipients who did not respond (not achieving Ն20% reduction from baseline in swollen and tender joint counts) were blindly advanced to tofacitinib, 5 mg or 10 mg twice daily. Tofacitinib recipients who did not respond at month 3 continued the same treatment and dose. At month 6, all patients still receiving placebo were blindly advanced to tofacitinib, 5 mg or 10 mg twice daily. Month 6 was considered an appropriate time to assess the primary end points-20% improvement in ACR (ACR20) criteria and rates of remission, defined by a Disease Activity Score for 28-joint counts based on the ESR (DAS28-4[ESR]) of less than 2.6 -because of current understanding of RA and expectations of when full potential treatment benefits probably occurred. The primary end point of the Health Assessment Questionnaire Disability Index (HAQ-DI) score was believed to be sufficiently sensitive to indicate an early treatment difference, and assessment at month 3 enabled a beneficial comparison of active treatment with a "pure" placebo, that is, before a proportion of patients initially receiving placebo were advanced at month 3 to active treatment.
Context
The response to disease-modifying drugs may be insufficient in many patients with rheumatoid arthritis (RA).
Contribution
In this randomized trial of patients with active RA despite the use of various disease-modifying regimens, the addition of tofacitinib resulted in improved disease activity compared with placebo.
Caution
Methotrexate, alone or in combination with other drugs, was the most common background therapy, and the ability to assess efficacy with other drugs or combinations is limited.
Implication
Tofacitinib may be an option for some patients with RA and an inadequate response to other treatments.
-The Editors
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Outcomes and Follow-up
Our primary objectives were to compare the efficacy of tofacitinib, 5 mg and 10 mg twice daily, with placebo assessed by the proportion of patients achieving an ACR20 (9) at month 6, the mean change from baseline in physical function status as measured by the HAQ-DI (10) at month 3, and the proportion of patients achieving DAS28-4(ESR)-defined remission (11) at month 6. "Response" was defined as a 20% improvement in the patient's tender or painful and swollen joint count at month 3 compared with baseline values. "Nonresponse" was defined as not achieving such improvement. This contrasts with the ACR's more stringent definition of the ACR20 response criteria, which requires the same 20% or more improvement in both joint counts plus a 20% or more improvement in 3 of the 5 remaining ACR core set measures of patient and physician global assessments, pain, disability, and an acute-phase reactant. An additional primary objective was to assess the safety of tofacitinib versus placebo over 12 months. Secondary objectives were to evaluate the ACR20, ACR50, and ACR70 response rates; change from baseline in HAQ-DI; DAS28-4(ESR) assessments; and Functional Assessment of Chronic Illness TherapyFatigue score over time.
The incidence and severity of all adverse events and clinical laboratory abnormalities were recorded, and vital sign assessments and physical examinations were routinely performed. To assess safety end points of cardiovascular events, a panel of independent experts (the Cardiovascular Safety Endpoint Adjudication Committee) reviewed all potential cardiovascular events and patient deaths regardless of cause.
Statistical Analysis
To control type I error rates, we assessed the 3 primary end points for efficacy in sequential order: ACR20, HAQ-DI, then DAS28-4(ESR) less than 2.6 ( Figure 1 of the Supplement). Doing so prevents the type I error rates (that is, the null hypotheses of no difference from placebo being mistakenly rejected when there is no difference) for the primary end points from becoming greater than 5% when statistical significance was measured. No preservation of type I error was applied for secondary end points, and a P value of 0.050 or less was considered statistically significant. The efficacy and safety analyses included all randomly assigned patients who received 1 or more doses of the study drug. The normal approximation for difference in binomial proportions was used to test the superiority of each tofacitinib dose against placebo with respect to ACR20 and the proportion of patients achieving DAS28-4(ESR) less than 2.6. Prespecified nonresponder imputation that addressed missing data in calculating ACR20 and DAS28-4(ESR) less than 2.6 was also applied to patients who had not achieved 20% improvement in tender and swollen joint counts, regardless of treatment assignment (placebo and active tofacitinib groups) at month 3. Nonresponder imputation analysis assumes that such patients did not respond to treatment for the remainder of the trial, even if they fulfill the ACR20 (or higher) or DAS28-4(ESR) less than 2.6 response criteria after 3 months. The HAQ-DI was expressed as the change from baseline and analyzed using a mixed-effect longitudinal model, with treatment and visit as fixed effects and patient as a random effect (estimates expressed as least-squares means). Comparisons with placebo for the first 6 months were analyzed by combining data from the 2 placebo sequences into 1 group. Secondary end points with binary variables were analyzed by nonresponder imputation, and continuous end points followed the analysis described for HAQ-DI. In addition, a multiple-imputation approach was implemented as a sensitivity analysis for rates of ACR20 and DAS28-4(ESR) less than 2.6 response, specifically to model the placebo response had placebo recipients continued placebo after month 3 and not advanced to tofacitinib treatment. See the Supplement for details of analysis and Appendix Table  1 for results (available at www.annals.org). We used SAS, version 9.2 (SAS Institute, Cary, North Carolina).
Safety data were summarized descriptively and as leastsquares means for selected variables. Formal testing of observed differences in safety measurements was not part of the statistical analysis plan in part because such testing is poorly defined and misleading for uncommon events.
Role of the Funding Source
The study design, collection of data, analysis, and interpretation of the results were funded by Pfizer. Pfizer employees participated in the study design and data analysis and interpretation. All authors had full access to all study data, and the corresponding author had final responsibility for the decision to submit the manuscript for publication.
RESULTS
Patient Disposition and Demographic Characteristics
Patients (n ϭ 795) were randomly assigned; 792 (99.6%) received 1 or more doses of study medication (the primary analysis set), and 651 (82.2%) completed the study (Figure 1) . Seven patients at 2 sites were identified to have site-specific violations of the Good Clinical Practice guidelines. Demographic and baseline characteristics are shown in Table 1 . Across treatment sequences, the mean age ranged from 50.8 to 53.3 years, 75.0% to 83.8% of patients were female, and the mean disease duration ranged from 8.1 to 10.2 years. During the study, 62.5% to 73.4% of patients continued to receive 1 background DMARD and 25.3% to 37.5% continued to receive 2 or more DMARDs. Methotrexate was the most frequently prescribed background DMARD (79.0% of all patients). The number of patients per background DMARD is shown in Table 1 of the Supplement.
Efficacy
Seventy-eight patients (49.1%) receiving placebo did not have a response at month 3 and advanced to tofacitinib, 5 mg (n ϭ 38) and 10 mg (n ϭ 40) twice daily; 80 (25.4%) and 58 (18.2%) patients randomly assigned to 5-mg and 10-mg twice-daily tofacitinib, respectively, also had no response at month 3. Forty-three patients (27%) receiving placebo met the ACR20 criteria at month 3.
The ACR20 response rates (month 6) were greater for the 5-mg twice-daily tofacitinib (treatment difference, 21.2% [95% CI, 12.2% to 30.3%]; P Ͻ 0.001) and 10-mg twice-daily tofacitinib (25.8% [CI, 16.8% to 34.8%]; P Ͻ 0.001) groups compared with the combined placebo group (Figure 2) . Improvements from baseline in HAQ-DI at month 3 were greater (P Ͻ 0.001) and the Excluded from laboratory data analysis (n = 5) § Three patients were randomly assigned but did not receive treatment, so they were not included in the efficacy analyses. * Patients randomly assigned to receive placebo for months 0 to 6 and then tofacitinib, 5 mg twice daily, for months 6 to 12. † Patients randomly assigned to receive placebo for months 0 to 6 and then tofacitinib, 10 mg twice daily, for months 6 to 12. ‡ Deaths are included in the "Discontinued" count. § Exclusion due to no laboratory data after baseline.
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proportions of patients with a DAS28-4(ESR) less than 2.6 at month 6 were greater for the 2 tofacitinib groups compared with placebo (P ϭ 0.005 for 5-mg twice-daily tofacitinib; P Ͻ 0.001 for 10-mg twice-daily tofacitinib) (Figure 2) .
Results from an analysis of the primary end points that excluded the 7 patients identified to have site-specific violations of the Good Clinical Practice guidelines are shown in Figure 2 of the Supplement.
Secondary Efficacy End Points
Over time, statistically significant response rates were observed for ACR20 and ACR50 by week 2 in both tofacitinib groups (Figure 3 [panels A and B] of the Supplement) and for ACR70 by week 2 (tofacitinib, 10 mg twice daily) and month 1 (tofacitinib, 5 mg twice daily) ( Figure  3 [panel C] of the Supplement). Mean treatment differences in changes from baseline in HAQ-DI, DAS28-4(ESR), DAS28-3(C-reactive protein), DAS28-4(ESR) less CCP ϭ cyclic citrullinated protein; DAS28-4(ESR) ϭ Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate; DMARD ϭ disease-modifying antirheumatic drug; ESR ϭ erythrocyte sedimentation rate; HAQ-DI ϭ Health Assessment Questionnaire Disability Index; NSAID ϭ nonsteroidal anti-inflammatory drug; RF ϭ rheumatoid factor; TNF ϭ tumor necrosis factor. * 19 countries were included in the study. † China, 218 (27.4%); Australia, 52 (6.5%); Thailand, 32 (4.0%); and Malaysia, 25 (3.1%). ‡ Wash-out periods: anakinra and etanercept must have been discontinued for 4 wk, adalimumab for 6 wk, infliximab for 8 wk, and abatacept and tocilizumab for 12 wk before the first dose of study drug. Rituximab or other selective B-lymphocyte-depleting agents (marketed or investigational) must have been discontinued for 1 y before the first dose of study drug and the CD19/20ϩ cell counts were normal by fluorescence-activated cell-sorting analysis. § Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab. Abatacept, baminercept, canakinumab, rituximab, and tocilizumab. Patients who did respond at 3 mo were considered not to have responded to treatment for the remainder of the trial, even if they subsequently achieved response after month 3. Error bars represent 95% CIs. ACR20 ϭ 20% improvement in American College of Rheumatology criteria; DAS28-4(ESR) ϭ Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate; HAQ-DI ϭ Health Assessment Questionnaire Disability Index; LSM ϭ least-squares mean; MCID ϭ minimum clinically important difference; NRI ϭ nonresponder imputation. * Patients who did not respond at month 3 were considered not to have responded to treatment for the remainder of the trial, even if they subsequently achieved response after month 3. † The numbers are different for DAS28-4(ESR) Ͻ2.6 because ESR was measured locally and some study sites were not able to collect these data.
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Safety and Tolerability
During months 0 to 12, the incidence rate (events per 100 patient-years) of adverse events was 171.9 (CI, 152.5 to 193.8) in the 5-mg twice-daily tofacitinib group, 175.7 (CI, 155.8 to 198.2) in the 10-mg twice-daily tofacitinib group, and 342.3 (CI, 281.1 to 416.9) in the combined placebo group. The corresponding incidence rates for serious adverse events were 6.9 (CI, 4.6 to 10.5), 7.3 (CI, 4.8 to 11.0), and 10.9 (CI, 4.9 to 24.2). These data, along with the incidence rates of adverse events leading to discontinuation, are shown in Table 2 . The most common adverse events during months 0 to 12 in the 5-mg and 10-mg twice-daily tofacitinib groups were upper respiratory tract infections (exposure-adjusted event rate [new events per 100 patient-years of exposure] of 12.3 and 14.6, respectively, vs. 12.6 in the combined placebo group), followed by nasopharyngitis (7.1 and 5.6, respectively, vs. 21.6 in the combined placebo group) ( Table 2 of the Supplement). Adverse events across groups in months 0 to 3, 4 to 6, and 7 to 12 and the incidence of adverse events, infectious events, and discontinuations are summarized in Appendix Table 2 (available at www.annals.org). We found no observable trends (no statistical analysis was done) in the type or severity of adverse events when the events were presented by background nonbiologic DMARD therapy ( Table 3 of the Supplement).
Four opportunistic infections occurred in patients receiving tofacitinib and were considered related to treatment by the investigators: disseminated (multidermatomal) herpes zoster, cryptococcal pneumonia, and 2 cases of pulmonary tuberculosis ( Table 4 of the Supplement). In months 0 to 3, serious infections occurred most frequently (n ϭ 4 [1.3%]) in the 10-mg twice-daily tofacitinib group (pneumonia [n ϭ 2], diabetic foot infection, and bronchiectasis) compared with the 5-mg twice-daily tofacitinib group (n ϭ 2 [0.6%]; bronchitis and disseminated herpes zoster) and the combined placebo group (0%). During months 6 to 12, only patients (n ϭ 3 [0.9%]) in the 10-mg twice-daily tofacitinib group reported serious infections (pulmonary tuberculosis [n ϭ 2], peritonitis, and cryptococcal pneumonia). Four deaths occurred ( Table 5 of the Supplement): 2 during the study (acute heart failure and respiratory failure in the 10-mg twice-daily tofacitinib group) and 2 after treatment discontinuation (traumatic brain injury 22 days after discontinuation and worsening RA 42 days after discontinuation in the 5-mg twice-daily tofacitinib group). One of the deaths, respiratory failure, was assessed by the investigator to be treatment-related.
Three patients had a potential cardiovascular event adjudicated by the Cardiovascular Safety Endpoint Adjudication Committee to meet criteria for ischemic and congestive heart failure events: transient ischemic attack (5-mg twice-daily tofacitinib), cerebrovascular accident (5-mg twice-daily tofacitinib), and congestive heart failure (10-mg twice-daily tofacitinib; patient subsequently died) ( Table 5 of the Supplement).
Mean changes from baseline in laboratory values over 12 months of treatment are shown in Appendix Table 2 . Mean neutrophil counts at month 3 decreased with tofacitinib versus placebo but stabilized thereafter to month 12. Increases in high-and low-density lipoprotein cholesterol levels versus placebo at month 3 were sustained until month 12. Cholesterol levels also increased in placebo recipients after they advanced to tofacitinib. Changes in AST and ALT levels did not differ among tofacitinib recipients who were also receiving various background nonbiologic DMARD therapy combinations, although the relatively small numbers of patients in the nonmethotrexate groups limit the strength of these investigations. The incidence of increased AST and ALT levels categorized by background nonbiologic DMARD are shown in Table 6 of the Supplement. Thirteen tofacitinib recipients discontinued therapy because of laboratory findings: increased AST or ALT levels (n ϭ 3), increased creatinine levels (n ϭ 4), and decreased neutrophil counts (n ϭ 2) ( Table 7 of the Supplement). No discontinuations occurred because of anemia.
DISCUSSION
The treatment of RA has improved in recent years because of the more aggressive use of nonbiologic DMARDs, either with a single DMARD or a combination, and the introduction of biologic therapies that may be used in combination with nonbiologic DMARDs. However, because treatment regimens are not effective in all patients and biologic agents are unavailable to some and require parenteral administration (12) (13) (14) (15) , a safe, effective, and tolerable oral DMARD is needed. Despite the common practice of prescribing nonbiologic DMARDs in combination, few randomized, prospective studies have investigated a new therapy in combination not only with methotrexate but also with other nonbiologic DMARDs.
Our study showed that when used in combination with various nonbiologic DMARDs, tofacitinib, 5 mg and 10 mg twice daily, compared with placebo rapidly reduced the signs and symptoms of RA and improved physical function. However, small sample sizes for patients receiving combinations of nonmethotrexate DMARDs lacked statistical power, and results should be interpreted cautiously.
These results support the findings of previous studies that demonstrated tofacitinib's efficacy in combination with methotrexate (16 -19) . We also observed the same safety events of special interest as seen in previous tofacitinib studies (6, 7, 16, 20) : infections, decreases in neutrophil counts, increases in high-and low-density lipoprotein cholesterol levels, and small increases in serum creatinine and aminotransaminase levels.
Of the 4 deaths, 1 (reported as respiratory failure by the investigator and as an infection by the Cardiovascular Safety Endpoint Adjudication Committee) was attributed to the study drug by the investigator. In all 4 deaths, the patients were receiving (or had received) tofacitinib. Four opportunistic infections were reported (all considered by the investigator to be related to the study drug): pulmonary tuberculosis (in 2 patients), disseminated (multidermatomal) herpes zoster, and cryptococcal pneumonia. The 2 patients with pulmonary tuberculosis lived in Thailand and China, countries classified by the World Health Organization as having a high burden of tuberculosis (21) .
We saw changes from baseline by month 3 in neutrophil counts, hemoglobin levels, and lipid levels, which stabilized thereafter. The mechanisms responsible for these changes are not fully understood. Mean neutrophil counts are known to decrease with various treatments and had decreased in a trial of adalimumab in patients with RA (19). Changes in hemoglobin are complex and may reflect improvement in the anemia of chronic disease and inhibition of erythropoietin signaling through JAK2. Elevation of lipids has also been reported with several biologic treatments and nonbiologic DMARDs with disease-modifying or anti-inflammatory activity in RA (22, 23) . A recent study has shown that for patients with RA treated with tofacitinib, atorvastatin, 10 mg daily, was effective in reducing low-density lipoprotein cholesterol levels to or below pretreatment levels (24). Small increases in mean serum creatinine levels of unknown mechanism were also observed during our study. Neutropenia, anemia, elevated aminotransaminase levels, and elevated creatinine levels often resolved spontaneously, or stabilized to acceptable levels, and infrequently caused discontinuation of therapy. These observations were also consistent with those of earlier studies of tofacitinib (6, 7, 16, 20) . Increased AST and ALT levels were not associated with any specific background nonbiologic DMARD therapy, although the small subset of sample sizes necessitates caution when interpreting results. Separate trials with longer-term monitoring of patients receiving tofacitinib are ongoing.
The limitations of this study include a smaller placebo group of relatively short duration compared with the tofacitinib sequences, although the study was powered to show statistically significant differences in efficacy. We did not stratify enrollment on the basis of background nonbiologic DMARD therapy, and patients receiving methotrexate or methotrexate in combination with another nonbiologic DMARD were predominantly enrolled. Sample sizes were therefore much lower for patients receiving combinations of nonmethotrexate DMARDs. In this context, results of the individual background nonbiologic DMARD subsets should be interpreted cautiously.
All patients, assessors, and intervention providers were blinded to therapy and measures of acute-phase reactants. The study investigators were not blinded to neutrophil counts because these had to be monitored for patient safety. Although we believe blinding was successful and there were no incidents of accidental unblinding, a formal analysis of the success of blinding was not done.
In summary, our study demonstrated that tofacitinib in combination with nonbiologic DMARDs, primarily methotrexate, was superior to placebo in rates of ACR20 response and DAS28-4(ESR)-defined remission and in improving HAQ-DI scores in patients with active RA. Safety events identified were consistent with those in previous tofacitinib studies: observed decreases in neutrophil counts, increases in high-and low-density lipoprotein cholesterol levels, and small increases in serum creatinine and aminotransaminase levels. Tofacitinib showed potential as an effective therapeutic agent in patients with RA who are currently receiving treatment with various nonbiologic 
